Latest Breaking News On - Foundation to eradicate duchenne - Page 5 : comparemela.com

Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Switzerland generalUnited statesUnited kingdomShabir hashamEric hoffmanEva kaliasReveragen biopharmaReveragen biopharma incSanthera pharmaceuticalsNational institutes of healthMuscular dystrophy association united statesDuchenne research fundFoundation to eradicate duchenneSanthera pharmaceuticals holdingEuropean commission horizonsHead investor relations communications

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference

Pratteln, Switzerland, and Rockville, MD, USA, June 9, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of new data with vamorolone in Duchenne muscular

Switzerland generalUnited statesUnited kingdomShabir hashamEric hoffmanEva kaliasReveragen biopharmaReveragen biopharma incSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthDuchenne research fundFoundation to eradicate duchenneHead global medical affairsSanthera pharmaceuticals holdingHead investor relations communications

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference

Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolerability data with vamorolone

Switzerland generalUnited statesUnited kingdomRyman hallEric hoffmanEva kaliasReveragen biopharmaMuscular dystrophy associationReveragen biopharma incSanthera pharmaceuticalsMuscular dystrophy association united statesNational institutes of healthHead external communicationsDuchenne research fundFoundation to eradicate duchenneSanthera pharmaceuticals holding

Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference

Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Switzerland generalUnited statesUnited kingdomRyman hallEva kaliasReveragen biopharmareveragenReveragen biopharmaeric hoffmanMuscular dystrophy associationReveragen biopharma incSanthera pharmaceuticalsNational institutes of healthMuscular dystrophy association united statesDuchenne research fundFoundation to eradicate duchenneSanthera pharmaceuticals holdingEuropean commission horizons

Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference

Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference  Pratteln, Switzerland, and Rockville, MD, USA, March 15, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of efficacy and tolera.

Switzerland generalUnited statesUnited kingdomRyman hallEric hoffmanEva kaliasReveragen biopharmaMuscular dystrophy associationReveragen biopharma incSanthera pharmaceuticalsNational institutes of healthMuscular dystrophy association united statesHead external communicationsDuchenne research fundFoundation to eradicate duchenneSanthera pharmaceuticals holding